Jeffrey Sobell is a Dermatology physician affiliated with Tufts Medical Center. OpenAlex indexes 40 publications with 751 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1244 Boylston St
Suite 302
Chestnut Hill, MA 024672116
Telephone
617-731-1600Registry record last updated 30 May 2012.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year2025122 payments$41,622openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202523 payments$26,654openpaymentsdata.cms.gov ↗
- Arcutis Biotherapeutics, Inc.Program year202519 payments$21,656openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.1%Interleukin-23 Antagonist88%Tildrakizumab99%Tremfya0%Skyrizi0%Skyrizi Pen0%Part D + Part B<11 patientsTNF inhibitor0.7%Humira(Cf) Pen51%Humira(Cf)36%Enbrel Sureclick13%Part D<11 patients+ 7 more classes in this area
Anti-infectives
2.7%Azole Antifungal0.7%Ketoconazole100%Part D≥61 patientsTetracycline-class Drug0.7%Doxycycline Hyclate58%Minocycline Hcl27%Doxycycline Ir-Dr15%Part D<11 patients+ 5 more classes in this area
Dermatology
2.4%Corticosteroid1.3%Triamcinolone Acetonide48%Triamcinolone acetonide28%Fluocinolone Acetonide25%Part D + Part B≥63 patientsInterleukin-4 Receptor alpha Antagonist0.7%Dupixent Pen63%Dupixent Syringe37%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Response to “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”
Journal of the American Academy of Dermatology
2026 - Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Dermatology and Therapy
2025 - Clinical Considerations for the Use of Biologic Agents in Psoriasis Patients With a History of Lymphoma
Journal of Psoriasis and Psoriatic Arthritis
2025 - 61999 Off-Label Applications of JAK Inhibitors in Connective Tissue Diseases
Journal of the American Academy of Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Levey, MD
Tufts Medical Center
Mark Sarnak, MD
Tufts Medical Center
James Udelson, MD
Tufts Medical Center
Nicholas Hill, MD
Tufts Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”